SynaptixBio
Study explores speech as marker in rare neurodegenerative disease
April 27, 2026Research and Development SynaptixBio, neurodegenerative disease
SynaptixBio has highlighted the potential of speech analysis as a non-invasive way to track disease progression in neurodegenerative conditions, as …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
Coriolis Pharma appoints Teun van der Heide as CEO
November 7, 2026
The evidence bar impacting UK medical cannabis access
November 6, 2026
